We would like to thank Robert de Meel and colleagues for their interest in and comments on our Article.
1 x 1 Howard, JF Jr, Utsugisawa, K, Benatar, M et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017; 16: 976–986 Google Scholar See all References The sub-analysis correlations between MG-ADL and QMG data in the phase 2 eculizumab trial
2 x 2 Howard, JF Jr, Freimer, M, O'Brien, F, Wang, JJ, Collins, SR, and Kissel, JT. QMG and MG-ADL correlations: study of eculizumab treatment of myasthenia gravis. Muscle Nerve. 2017; 56: 328–330 Google Scholar See all References were based on change from baseline to week 16 in 13 patients who were refractory to immunosuppressive treatments. No correlation analyses have been done on the phase 3 worst-rank data.